Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2025
Reporting Period: Event-based disclosure regarding clinical trial updates.
Business Context: The Company is an emerging growth company focused on developing investigational intranasal agents. This filing discloses updated clinical results for NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma.
Key Financial Metrics
This Form 8-K is a disclosure of material non-financial events (Regulation FD) and does not contain audited or unaudited financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change disclosed is the release of updated clinical data:
- Clinical Study Update: Announcement of results from Phase 1/2a and compassionate care studies.
- Patient Cohort: Data involves a cohort of 24 patients.
- Indication: Treatment of recurrent WHO Grade III/IV isocitrate dehydrogenase 1 (IDH1)-mutant astrocytoma.
- Investigational Agent: NEO100 (intranasal agent).
Guidance, Outlook, and Management Commentary
Management Commentary: The Company hosted an investor conference call on November 12, 2025, to discuss the clinical results. An investor presentation and transcript were furnished as exhibits (99.2 and 99.3).
Guidance and Risks: The filing text does not provide specific forward-looking financial guidance, updated risk factors, or contingencies beyond the standard regulatory language regarding the non-filing status of the press release and presentation materials.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific efficacy and safety data points regarding the 24-patient cohort.
- Examine Exhibit 99.2 (Investor Presentation) for management's interpretation of the clinical results and future development plans.
- Consult Exhibit 99.3 (Transcript) for Q&A details regarding the timeline for subsequent trial phases or regulatory submissions.
- Verify the Company's cash runway and liquidity status in the most recent 10-Q or 10-K, as this 8-K does not contain financial data.